We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
+8.58%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$391M
AUM Growth
+$18.9M
Cap. Flow
+$55.5M
Cap. Flow %
14.18%
Top 10 Hldgs %
80.82%
Holding
26
New
5
Increased
1
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$118M
2
KYNB
Kyntra Bio
KYNB
+$7.49M
3
MRSN
Mersana Therapeutics
MRSN
+$6.65M
4
SPRB
Spruce Biosciences
SPRB
+$5.85M
5
VKTX icon
Viking Therapeutics
VKTX
+$3.62M

Top Sells

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$60.7M
2
SCPH
scPharmaceuticals
SCPH
+$11.2M
3
JANX icon
Janux Therapeutics
JANX
+$5.88M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$5.46M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.19M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CINC
26
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
– –
-4,937,646
Closed -$60.7M
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q1 2023 Portfolio in Review

As of Q1 2023, 5AM Venture Management held 26 positions worth $391M, up 5.1% from $372M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

5AM Venture Management deployed $55.5M of net new capital in Q1 2023, opening 5 new positions and adding to 1 existing holding. Its largest new stake was Enliven Therapeutics: 5,798,475 shares worth $127M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was scPharmaceuticals, an estimated $11.2M trimmed.

  • 5AM Venture Management's largest Q1 2023 buy was Enliven Therapeutics: 5,798,475 shares worth $127M.
  • 5AM Venture Management added most to Kyntra Bio in Q1 2023, an estimated $7.49M increase.
  • 5AM Venture Management's biggest Q1 2023 reduction was scPharmaceuticals, cutting an estimated $11.2M.
  • 5AM Venture Management fully exited CinCor Pharma, Inc. Common Stock in Q1 2023, selling an estimated $60.7M.
  • 5AM Venture Management's ten largest holdings make up 81% of its $391M portfolio in Q1 2023.
  • 5AM Venture Management opened 5 new positions and closed 2 in Q1 2023.
  • 5AM Venture Management's portfolio value rose 5.1% quarter-over-quarter to $391M.

Based on 5AM Venture Management's 13F filing for Q1 2023, filed 15 May 2023.